Funding profile · Cardiac imaging AI

InVision Medical Technology

Two FDA clearances, a CPT code and a Medicare add-on payment, on about $500,000 of disclosed outside capital and no Form D at all. The interesting number here is the one that is missing.

Data as of September 22, 2026. Company-reported figures are labeled. Note that InVision is a common name; every record below was checked against the cardiac imaging company incorporated as InVision Medical Technology Corporation.

Rounds at a glance

What the filings show

Reading the filings

1. Two device clearances on half a million dollars of disclosed capital.The FDA record shows how. Both 510(k) submissions were prepared by an outside regulatory consultant, Golnaz Moeini of MedEdge Consulting, with the applicant contact listed as co-founder David Ouyang.
2. The money that paid for the science is not the company’s money.The randomized trial behind the ejection fraction product, NCT05140642, was sponsored by Cedars-Sinai Medical Center and records no outside funding. The 2025 international validation was funded by NIH grants R00HL157421, R01HL173526 and R01HL173487 to David Ouyang plus a grant from Alexion AstraZeneca Rare Disease, and the cirrhosis trial by the American Heart Association. On the company balance sheet, validation cost close to nothing.
3. Reimbursement is the revenue model, and it is not revenue yet.Two rates are now set: $313 for the hospital outpatient technical component of CPT 0932T under APC 5743, and up to $2,275 per eligible Medicare inpatient stay under the add-on effective October 1, 2026. Both are paid to the hospital, not to InVision. What the hospital pays InVision is not public, so neither the gross margin nor the revenue per study can be derived from these numbers.
4. The pathway that produced the add-on is being closed.Per the American College of Cardiology summary of the FY 2027 final rule, the add-on alternative pathway for Breakthrough Devices is repealed beginning with 2028 applications. Of eleven cardiovascular applications this cycle, three were withdrawn, seven approved and one denied. InVision is inside the last cohort that route will produce.
5. Headcount and revenue estimates differ by an order of magnitude.The Y Combinator directory still lists team size 2 and a San Francisco location, while the FDA filings and CB Insights both place the company at 9702 Cisco Street, Los Angeles. One data provider models about 19 staff and roughly $2.1 million of 2025 revenue; another lists a headcount of 1. None is a reported figure.
6. A conflict disclosure worth reading.The 2025 validation paper discloses that David Ouyang holds consulting fees and equity in Ultromics as well as InVision. Ultromics builds EchoGo Amyloidosis, which is the predicate device for InVision’s amyloid clearance and the comparator in the independent head-to-head study.

Commercial signals

What to watch

• A first Form D, or a reported priced round. Either would be the first hard capital datapoint since 2022.
• Whether the add-on translates into billed claims. The code is live from October 1, 2026, so the first year of utilization data will settle it.
• Registration of the American Heart Association funded cirrhosis trial, and a second clearance built on it.
• Regulatory approval in Australia and New Zealand, which gates the HeartLab channel.
• Whether the company ever publishes headcount, customers or revenue.

The InVision Medical Technology story on Healthcare DiscoveryHealthcare Discovery

Related companies

• Medplum: Shared investor: Gaingels. An open source, FHIR native electronic health record that developers install instead of licensing
• Pair Team: Shared investor: Gaingels. A California medical group delivering Medicaid Enhanced Care Management to people living in shelters, cars and encampments
• BrainKey: Shared investor: Amino Capital. A San Francisco company that turns an ordinary brain MRI into a 3D dashboard and a single number it calls BrainAge
• Zeit Medical: Shared investor: Gaingels. A soft EEG headband built to notice a stroke while its wearer is asleep and raise the alarm before anyone else can

Sources

1. Public recordSEC EDGAR company search and full text search for InVision Medical TechnologySEC · searched Sep 22, 2026
2. Public recordFDA 510(k) clearance letter and summary, K232331FDA · Apr 25, 2024
3. Public recordFDA 510(k) clearance letter and summary, K243866FDA · May 21, 2025
4. Public recordInternational Validation of Echocardiographic Artificial Intelligence Amyloid Detection Algorithm, funding and disclosure statementJACC: Advances · Nov 2025
5. Public recordClinicalTrials.gov record NCT05140642ClinicalTrials.gov · last update posted Jul 5, 2022
6. Public recordFY 2027 Hospital Inpatient Prospective Payment System final rule fact sheetCMS · Jul 31, 2026
7. IndependentCMS Releases 2027 IPPS Final RuleAmerican College of Cardiology · Aug 5, 2026
8. IndependentNews: FY 2027 ICD-10-PCS code set and guidelines releasedACDIS · Jun 18, 2026
9. IndependentInVision company profile, total raised and investor listCB Insights · accessed Sep 22, 2026
10. IndependentInVision Medical Technology funding rounds and investorsCaplight · accessed Sep 22, 2026
11. IndependentHeartLab announces partnership with InVision Medical TechnologyHeartLab · Oct 13, 2025
12. CompanyReimbursement page, CPT 0932T and Medicare add-on ratesInVision Medical Technology · accessed Sep 22, 2026
13. CompanyAlexion collaboration and Breakthrough Device releasesInVision Medical Technology · Nov 2023 to Nov 2025
14. CompanyInVision Medical Technology company page, Summer 2022 batchY Combinator · accessed Sep 22, 2026

Compiled from SEC, FDA, CMS and ClinicalTrials.gov public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; companies that raise under Section 4(a)(2) file none, so the absence of a notice does not establish the absence of a financing. Healthcare Venture Capital Fund holds no position in InVision Medical Technology. This page is not an offer to sell or a recommendation to buy any security.